aTyr Pharma, Inc.
ATYR
$3.28
$0.185.81%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -27.06% | -47.89% | -28.51% | -19.48% | -11.14% |
| Total Depreciation and Amortization | -43.82% | -35.73% | 4.12% | 28.07% | 61.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 148.21% | -174.65% | -148.62% | -138.25% | -122.59% |
| Change in Net Operating Assets | -146.08% | -168.06% | -223.14% | -135.55% | 1,902.16% |
| Cash from Operations | -108.06% | -106.13% | -80.00% | -70.01% | 20.69% |
| Capital Expenditure | 98.46% | 98.93% | 88.45% | -4.99% | -156.86% |
| Sale of Property, Plant, and Equipment | -53.33% | -100.00% | -100.00% | 50.00% | -91.62% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 208.56% | 234.42% | 294.04% | 823.06% | -132.70% |
| Cash from Investing | 185.62% | 214.44% | 240.11% | 400.54% | -142.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -26.14% | -40.29% | -97.05% | -240.15% | -496.97% |
| Issuance of Common Stock | -39.42% | -55.17% | -50.86% | -53.52% | 1,107.61% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -39.81% | -55.72% | -51.43% | -54.24% | 1,115.01% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -193.32% | 115.57% | -192.57% | -189.08% | 19.17% |